Citigroup has placed Cipla on a 90-day 'Positive Catalyst Watch,' citing potential US product approvals and a recovery in its domestic business. The brokerage highlights expected momentum from key drug launches and a potential USFDA clearance for the company's Indore facility.
What Happened
Citigroup has initiated a 90-day 'Positive Catalyst Watch' on Cipla, citing multiple factors that could improve the pharmaceutical company's growth in the coming months. The brokerage remains optimistic about the company's prospects, pointing toward a rebound in both its US and Indian business segments. This development reflects confidence that the company's earnings, which faced pressure following the decline of its gRevlimid product, may have reached a low point and are now poised for a turnaround.
The US Growth Drivers
For the US market, analysts at Citigroup expect a series of upcoming events to act as growth triggers. The company is anticipating key product approvals, specifically for gFlovent from its Goa manufacturing facility. Additionally, the planned launch of gVentolin is considered a significant near-term opportunity. The company has already demonstrated a strong presence in the US with its Nintedanib product, where it holds nearly 50 percent of the market share. These factors, combined with an expected revenue rebound, form the core of the positive outlook for its international business.
Domestic Business And Regulatory Focus
Back in India, Cipla's performance is being supported by a recovery in its respiratory product portfolio, which remains a key revenue driver. A crucial factor for investors to track in the coming months is the regulatory status of the company's Indore plant. The facility is scheduled for a re-inspection, and a successful USFDA clearance could provide a notable boost to the company's manufacturing and supply capabilities. Furthermore, easing geopolitical tensions are seen as a positive, potentially reducing raw material costs and helping protect profit margins.
Valuation And Peer Comparison
From a valuation perspective, Citigroup notes that Cipla is trading at approximately 25 times its estimated earnings for FY27 and 21 times for FY28. When comparing domestic exposure, the brokerage suggests that Cipla offers an attractive risk-reward profile. For instance, the company’s India business is valued at about 7.8 times its FY26 sales, which appears relatively more attractive compared to some peers, such as Mankind Pharma, which trades at 8.5 times. This valuation gap, along with the expected operational recovery, is why the brokerage views the current stock level as an interesting point for the business.
What Investors Should Track Next
The immediate monitorables for investors will be the official updates regarding US drug approvals and the outcome of the USFDA inspection at the Indore site. Any news regarding the launch of gVentolin or updates on the gFlovent approval process will also be important for gauging the pace of US revenue recovery. Additionally, tracking the profit margin trends in the domestic respiratory business will help verify whether the current recovery is sustainable.